The GRIPHON study demonstrated that selexipag is the first nonprostanoid agonist of the prostacyclin receptor that can reduce the risk of PAH disease progression, lower the morbidity/mortality composite endpoint, and delay PAH progression.11, 12, 13, 14. The gene discussed is PTGIR; the disease is pulmonary arterial hypertension.